Cargando…
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
Introduction: Lung cancer (LC) is the most common neoplasm worldwide, and 85% of these tumors are classified as non-small cell lung cancer (NSCLC). LC treatment was initially restricted to cytotoxic chemotherapy—platinum compounds associated with 3rd generation cytotoxic agents (paclitaxel, gemcitab...
Autores principales: | de Mello, Ramon Andrade, Neves, Nathália Moisés, Tadokoro, Hakaru, Amaral, Giovanna Araújo, Castelo-Branco, Pedro, Zia, Victor André de Almeida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693900/ https://www.ncbi.nlm.nih.gov/pubmed/33153004 http://dx.doi.org/10.3390/jcm9113543 |
Ejemplares similares
-
The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
por: De Mello, Ramon Andrade, et al.
Publicado: (2020) -
Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives
por: De Mello, Ramon Andrade Bezerra, et al.
Publicado: (2021) -
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2017) -
CRISPR-based strategies in infectious disease diagnosis and therapy
por: Binnie, Alexandra, et al.
Publicado: (2021) -
Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?
por: Almeida-Lousada, Hélder, et al.
Publicado: (2021)